4//SEC Filing
Pacala Mark L 4
Accession 0001079973-25-000525
CIK 0001799191other
Filed
Mar 27, 8:00 PM ET
Accepted
Mar 28, 5:41 PM ET
Size
8.9 KB
Accession
0001079973-25-000525
Insider Transaction Report
Form 4
Pacala Mark L
Director
Transactions
- Purchase
Common Stock
2025-03-26$1.04/sh+90,562$94,338→ 224,971 total(indirect: By LLC) - Purchase
Common Warrant
2025-03-26$0.13/sh+42,281$5,285→ 42,281 total(indirect: By LLC)Exercise: $1.20From: 2025-03-26Exp: 2030-03-26→ Common Stock (42,281 underlying)
Footnotes (4)
- [F1]Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").
- [F2]Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250.
- [F3]Securities were purchased by Pacala Enterprises, LLC, an entity controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein.
- [F4]The holder may not exercise any portion of a Common Warrant to the extent that the holder would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Securities Exchange Act of 1934, as amended.
Documents
Issuer
Oncology Institute, Inc.
CIK 0001799191
Entity typeother
Related Parties
1- filerCIK 0001321250
Filing Metadata
- Form type
- 4
- Filed
- Mar 27, 8:00 PM ET
- Accepted
- Mar 28, 5:41 PM ET
- Size
- 8.9 KB